Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of VGXI.

    Client Virtual Booth

    VGXI

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    VGXI
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2700 Research Forest Drive Suite 180 The Woodlands, Texas 77381
    Telephone
    Telephone
    281-296-7300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vgxii.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vgxi-inc/
    Twitter
    Twitter
    https://twitter.com/vgxi?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    VGXI, Sutro Partner to Support Sutro's Clinical Pipeline

    Details:

    The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.


    Lead Product(s): Luveltamab Tazevibulin,Pegfilgrastim

    Therapeutic Area: Oncology Product Name: Luvelta

    Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Sutro Biopharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership June 03, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies

    Details:

    Geneos Therapeutics, Inc. has executed a new purchasing contract under their current Clinical Manufacturing Supply Agreement to support the expansion of the ongoing clinical trial for GNOS-PV02.


    Lead Product(s): GT-30,INO-9012,Pembrolizumab

    Therapeutic Area: Oncology Product Name: GNOS-PV02

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Geneos Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership March 16, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search